Temozolomide - Latest Advances

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 12, 2025

Pretargeted Polymeric Systems for Conducting Chemo-Radiotherapy on Glioblastoma: An Evaluation of the Impact of Nanomedicine Structure on Bioorthogonal Chemistry In Vivo.

Journal: Biomacromolecules

Published: December 11, 2025

Real-world use of non-oral administration of oral anticancer agents via the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis.

Journal: Drug discoveries & therapeutics

Published: December 10, 2025

BCL11A-triggered IFI6 inhibition reduces glioma cell resistance to temozolomide by promoting ferroptosis.

Journal: Neurological research

Published: December 10, 2025

Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme.

Journal: Journal of proteome research

Published: December 05, 2025

CPUK02 sensitizes U87 glioblastoma cell lines to TMZ treatment via autophagy flux inhibition.

Journal: Molecular biology research communications

Published: December 05, 2025

Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up.

Journal: Proceedings (Baylor University. Medical Center)

Published: December 04, 2025

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 01, 2025

POT1-AS1/IGF2BP2/GPX4 promotes temozolomide resistance and radioresistance in glioblastoma by inhibiting ferroptosis.

Journal: International journal of radiation biology

Published: December 01, 2025

Engineering spatially defined extracellular matrix gradients to govern self-organized multicellular aggregates in a glioblastoma-on-a-chip.

Journal: Lab on a chip

Published: November 27, 2025

Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastoma.

Journal: bioRxiv : the preprint server for biology

Published: November 26, 2025

Adaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients.

Journal: medRxiv : the preprint server for health sciences

Published: November 26, 2025

Filters

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.

Pretargeted Polymeric Systems for Conducting Chemo-Radiotherapy on Glioblastoma: An Evaluation of the Impact of Nanomedicine Structure on Bioorthogonal Chemistry In Vivo.

Pretargeted Polymeric Systems for Conducting Chemo-Radiotherapy on Glioblastoma: An Evaluation of the Impact of Nanomedicine Structure on Bioorthogonal Chemistry In Vivo.

Real-world use of non-oral administration of oral anticancer agents via the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis.

Real-world use of non-oral administration of oral anticancer agents via the simple suspension method in Japanese patients with cancer: A nationwide claims-based analysis.

BCL11A-triggered IFI6 inhibition reduces glioma cell resistance to temozolomide by promoting ferroptosis.

BCL11A-triggered IFI6 inhibition reduces glioma cell resistance to temozolomide by promoting ferroptosis.

Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme.

Mitochondrial Metabolic Reprogramming along with NRF2/KEAP1-Mediated Antioxidant Mechanisms Drive Temozolomide Resistance in Glioblastoma Multiforme.

CPUK02 sensitizes U87 glioblastoma cell lines to TMZ treatment via autophagy flux inhibition.

CPUK02 sensitizes U87 glioblastoma cell lines to TMZ treatment via autophagy flux inhibition.

Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up.

Long-term survival in a patient with metastatic prolactinoma: a 12-year follow-up.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

POT1-AS1/IGF2BP2/GPX4 promotes temozolomide resistance and radioresistance in glioblastoma by inhibiting ferroptosis.

POT1-AS1/IGF2BP2/GPX4 promotes temozolomide resistance and radioresistance in glioblastoma by inhibiting ferroptosis.

Engineering spatially defined extracellular matrix gradients to govern self-organized multicellular aggregates in a glioblastoma-on-a-chip.

Engineering spatially defined extracellular matrix gradients to govern self-organized multicellular aggregates in a glioblastoma-on-a-chip.

Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastoma.

Systems analysis uncovers early temozolomide responses and peptide antigens in glioblastoma.

Adaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients.

Adaptive nuclear GTP synthesis promotes glioblastoma treatment resistance and is a targetable vulnerability in patients.